Trial Profile

A study identifying which biomarkers are predictive of a good clinical response following treatment with Xolair in patients with severe asthma

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Sep 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omalizumab (Primary)
Indications Asthma
Focus Biomarker; Pharmacodynamics
Acronyms SoMOSA
Sponsors Novartis

Most Recent Events

31 Jan 2018 Status changed from recruiting to active, no longer recruiting.
31 Jan 2018 Planned End Date changed from 30 Sep 2019 to 31 Aug 2019.
29 Jan 2018 Status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com